Invention Application
- Patent Title: METABOLITES OF GLP1R AGONISTS
-
Application No.: US17546207Application Date: 2021-12-09
-
Publication No.: US20220213072A1Publication Date: 2022-07-07
- Inventor: Andrew John Bessire , David James Edmonds , David Andrew Griffith , Amit Sumant Kalgutkar , Timothy Frank Ryder
- Applicant: Pfizer Inc.
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.
- Current Assignee: Pfizer Inc.
- Current Assignee Address: US NY New York
- Main IPC: C07D405/14
- IPC: C07D405/14 ; C07D401/14
Abstract:
The present invention provides compounds of Formula XA-1, XA-2, XA-3, XA-4, XA-5, or XA-6, or metabolites of Compound 1 or metabolites of a compound of Formula I, PA-I, or PA-III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I, PA-1, or PA-III.
Public/Granted literature
- US12065434B2 Metabolites of GLP1R agonists Public/Granted day:2024-08-20
Information query
